Ronald Berger, MD
Cardiovascular Disease · Bannockburn, ILNPI 1730109851
Payments from drug & device makers
Across 517 payments — averaging $290.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Irhythm Technologies, Inc.$129K
- Boehringer Ingelheim$7K
- Novo Nordisk$2K
- Johnson & Johnson$2K
- Novartis$2K
- Medtronic$1K
- plus $6K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Irhythm Technologies, Inc. | 42 | $129,255 |
| Boehringer Ingelheim | 42 | $6,829 |
| Novo Nordisk | 55 | $2,401 |
| Johnson & Johnson | 55 | $1,998 |
| Novartis | 75 | $1,832 |
| Medtronic(2 entities) | 30 | $1,495 |
| Amgen | 28 | $1,053 |
| AstraZeneca | 40 | $875 |
| E.r. Squibb & Sons, L.L.C. | 45 | $847 |
| Boston Scientific | 25 | $574 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $438 |
| Pfizer | 17 | $414 |
| Abbott | 10 | $285 |
| Sanofi-aventis U.S. LLC | 2 | $207 |
| Edwards Lifesciences | 2 | $202 |
| Impulse Dynamics (USA) Inc. | 1 | $176 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $129 |
| Cvrx, Inc. | 2 | $116 |
| Actelion Pharmaceuticals US, Inc. | 3 | $114 |
| Biosense Webster, Inc. | 3 | $111 |
| Janssen Scientific Affairs, LLC | 1 | $103 |
| Merck | 4 | $99 |
| Abiomed | 3 | $92 |
| Scpharmaceuticals Inc. | 3 | $59 |
| Lexicon Pharmaceuticals, Inc. | 3 | $55 |
| Alnylam Pharmaceuticals Inc. | 2 | $52 |
| Philips North America LLC | 1 | $51 |
| Bayer | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Davol Inc. | 1 | $26 |
| Coloplast | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$150,078 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Bannockburn
- Jay AlexanderBannockburn$744K
- David DavidsonBannockburn$481K
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Lokesh ChandraHazel Crest$2.7M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.